Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Akero Therapeutics Inc shares valued at $200,000 were sold by Lamy Patrick on May 22 ’25. At $50.00 per share, Lamy Patrick sold 4,000 shares. The insider’s holdings dropped to 33,492 shares worth approximately $1.61 million following the completion of this transaction.
Also, PATRICK D LAMY purchased 10,000 shares, netting a total of over 483,500 in proceeds.
Before that, Yale Catriona had sold 10,000 shares from its account. In a trade valued at $392,978, the Chief Development Officer traded Akero Therapeutics Inc shares for $39.30 each. Upon closing the transaction, the insider’s holdings decreased to 10,000 shares, worth approximately $4.56 million.
As published in a research note from BofA Securities on January 30, 2025, Akero Therapeutics Inc [AKRO] has been rated up from a Neutral to a Buy and the price target has been revised to $63 from $35. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in late January. As of November 18, 2024, Citigroup has initiated its “Buy” rating for AKRO.
Analyzing AKRO Stock Performance
During the last five days, there has been a drop of approximately -0.66%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 72.65%. Shares of the company reached a 52-week high of $58.40 on 01/27/25 and a 52-week low of $21.34 on 01/14/25.
Support And Resistance Levels for Akero Therapeutics Inc (AKRO)
According to the 24-hour chart, there is a support level at 45.71, which, if violated, would cause prices to drop to 43.40. In the upper region, resistance lies at 49.57. The next price resistance is at 51.12. RSI (Relative Strength Index) is 60.65 on the 14-day chart, showing neutral technical sentiment.
